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Summary Cardiovascular complications in Turner’s syndrome are the most common cause of
excess early mortality, with a life expectancy that may be reduced by more than 10 years.
Congenital cardiac abnormalities are described in approximately one third of patients. These
abnormalities are mostly left heart obstructions, the most common of which are bicuspid aortic
valve (16%) and coarctation of the aorta (11%). Dilatations of the ascending aorta are often
described and may occur in isolation from any heart disease, suggesting a vasculopathy spe-
ciﬁc to the syndrome, probably predisposed to by extracardiac risk factors such as oestrogen
deﬁciency, diabetes, dysplidaemia and overweight. The most feared complication is aortic
dissection with around a 100 cases, described at average age of approximately 35-years-old.
This is believed to complicate 2% of induced pregnancies. Hypertension (HBP) usually essen-
tial, affects up to 50% of patients with Turner’s syndrome. This is an important risk factor
for cardiovascular complications and justiﬁes aggressive treatment. On the other hand, retro-
spective studies have not demonstrated adverse cardiological effects due to growth hormone
treatments. Patients with Turner’s syndrome merit regular cardiology follow-up from childhood
onwards, particularly if they have treated heart disease. The merits of preventative treatments
for aortic dilatation have not been demonstrated in Turner’s syndrome and justify prospective
trials.
© 2008 Published by Elsevier Masson SAS.
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Résumé Dans le syndrome de Turner, les complications cardiovasculaires sont les principales
responsables d’une surmortalité précoce avec une espérance de vie qui pourrait être réduite de
plus de dix ans. Des anomalies cardiaques congénitales sont décrites chez environ un tiers des
patientes. Ces cardiopathies sont essentiellement des obstacles du cœur gauche dont les plus
fréquents sont la bicuspidie aortique (16 %) et la coarctation aortique (11 %). Des dilatations de
l’aorte ascendante sont fréquemment décrites, y compris en l’absence de cardiopathie, faisant
évoquer une vasculopathie propre au syndrome probablement favorisée par des facteurs de
risque extracardiaques tels que : la carence en estrogène, le diabète, une dyslipidémie, une
surcharge pondérale. La dissection aortique en est la complication la plus redoutable avec
près d’une centaine de cas décrits à un âge moyen proche de 35 ans. Elle compliquerait 2 %
des grossesses induites. L’hypertension artérielle (HTA), le plus souvent essentielle concerne
jusqu’à 50% des patientes avec syndrome de Turner. C’est un facteur de risque important de
complications cardiovasculaires qui justiﬁe un traitement rigoureux. En revanche, les études
rétrospectives n’ont pas montré d’effets délétères cardiologiques des traitements par hormone
de croissance. Les patientes avec syndrome de Turner justiﬁent une surveillance cardiologique
régulière dès l’enfance, notamment en cas de cardiopathie traitée. L’intérêt de traitements
préventifs de la dilatation aortique n’a pas été démontré dans le syndrome de Turner et justi-
ves.
r Ma
I
T
1
X
g
H
m
s
m
o
c
e
r
C
s
C
C
i
c
a
i
t
l
a
t
l
b
(
v
a
f
v
M
a
m
t
l
A
T
a
o
d
T
t
d
[
c
X
v
t
t
a
p
L
P
o
e
p
ﬁ
p
n
h
b
p
o
a
a
oﬁerait des études prospecti
© 2008 Published by Elsevie
ntroduction
urner’s syndrome, which has a prevalence at birth of
/2500 girls, is due to complete or partial absence of an
chromosome and is almost invariably associated with
rowth retardation and ovarian failure with infertility.
eight prognosis is improved by growth hormone treat-
ents. Pregnancies can occasionally be considered either
pontaneously, particularly in mosaics, or after assisted
edical conception (oocyte donation) in patients with-
ut appropriately monitored complications. Cardiovascular
omplications are those which are mostly responsible for
arly excess mortality and the life expectancy may be
educed by more than 10 years [1].
ardiovascular abnormalities and Turner’s
yndrome
ongenital heart disease
ongenital cardiac abnormalities are described in approx-
mately 30% of cases (23 to 45%) [2—4]. These are more
ommon in series in which the cardiology assessment used
combination of echocardiography and magnetic resonance
maging (MRI). This technique demonstrates abnormalities,
he clinical signiﬁcance of which remains to be estab-
ished [5—7]. The incidence is higher in 45 X monosomies
nd rarer (20%) in mosaics or in people with a struc-
ural X abnormality. The main cardiac abnormalities are
eft heart obstructions, the most common of which are
icuspid aortic valve (16%) and coarctation of the aorta
11%). These two anomalies may be combined [8]. Aortic
alve dysplasia without a bicuspid valve and mitral valve
bnormalities (ballooning, ‘‘parachute valve’’) are also
ound.Pulmonary and systemic (persistent superior vena cava)
enous return abnormalities were seen in 13% of cases in an
RI study. Pulmonary venous return abnormalities, which
re estimated to have a prevalence of approximately 3%,
ay be haemodynamically signiﬁcant and result in correc-
o
i
r
p
osson SAS.
ive surgery being offered depending on the extent of the
eft—right shunt [9,10].
ntenatal diagnosis
he antenatal diagnosis of Turner’s syndrome is suggested as
result of ultrasound abnormalities: mostly cystic hygroma
r even anasarca, with a high incidence of congenital heart
isease (60%) and spontaneous early fetal death [11—13].
he association between fetal jugular lymphatic obstruc-
ion responsible for cystic hygroma and congenital heart
isease, particularly of the left side, has been established
14]. Haplo-insufﬁciency of genes not yet isolated and asso-
iated with ‘‘X’’ in the pseudo-autosomal region primary
p involved in vascular morphogenesis may also explain the
ascular and lymphatic abnormalities [15,16]. The congeni-
al heart diseases found in utero are mostly coarctations of
he aorta (45%) or hypoplastic left heart (13%). These have
poor prognosis and most result in medical termination of
regnancy or spontaneous fetal death [11].
eft side obstructive abnormalities
ostnatally, left heart hypoplasia only therefore affects 2%
f children with Turner’s syndrome. The only study that
xamined the prognosis of the Norwood procedure in this
opulation showed a very poor prognosis: 15% survival at
ve years compared to 60% in non-syndromic patients [17].
When coarctation of the aorta is not suspected during
regnancy from ventricular asymmetry, it is usually diag-
osed clinically in the ﬁrst weeks of life. In some cases
owever it is diagnosed later in older children or adults
y echocardiography or even MRI or aortic CT angiogra-
hy. These investigations can detect unusual angulations
r elongations of the aortic arch without repercussions
ffecting up to 50% of patients with Turner’s syndrome,
lthough these have not been shown to increase the risk
f aortic dissection [6]. Treatment is usually surgical if the
bstruction is signiﬁcant (more than 50%) and the patient
s hypertensive and usually has very good postoperative
esults, morbidity mostly being due to the frequency of
ostoperative hypertension. Percutaneous angioplasty with
r without stenting has been performed in native coarcta-
even
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tions or recoarctations, with encouraging preliminary results
[17]. Nevertheless a recent clinical case describes fatal dis-
section of the descending aorta after stenting in a young
19-years-old Turner’s woman [18]. An aortic valve abnor-
mality, usually bicuspid valve, may be isolated and silent
and only detected by echocardiography or even MRI. The
features of aortic bicuspid valve and its risks of progression
are similar in syndromic patients to the overall population.
If discovered, patients should be treated to prevent risks
of endocarditis with antibiotic prophylaxis for at risk proce-
dures (dental care, surgical procedures). Regular follow-up
will detect the development of complications: aortic steno-
sis and/or insufﬁciency, aortic dilatation and prevent the
risks of dissection.
Acquired aortic abnormalities
Aortic dilatation
Aortic dilatation mostly affects the aortic root and ascend-
ing aorta. As proposed for Marfan’s syndrome, ascending
aorta measurements are performed following the Roman
recommendations on a left long axis parasternal view in
end-diastole and assessed as a function of age and body
surface area [19]. Nevertheless, the very deﬁnition of a
dilated aorta raises a problem in this population in the
absence of standard values appropriate for small patient
height. The 95th percentile dimensions of the ascending
aorta, i.e. 20mm/m2 equivalent to values between 28 and
32mm at the sinus of Valsalva, are abnormal in 24 to 42% of
adult patients, far more than the 6.5% prevalence of aor-
tic dilatation reported in the Lin study [6,7,20—23]. The
ratio of ascending/descending aorta diameters which has
the advantage of being unrelated to body surface area, is
abnormal, i.e. more than 1,5 in one thirds of the patients
with no history of coarctation. Dilatation is found primarily
in patients with HBP and or bicuspid aortic valve or a past
history of coarctation of the aorta, although may be found
in the absence of any cardiological abnormalities. Arterial
dilatations may extend to more distal vessels such as the
carotid and brachial arteries [23]. Finally, carotid intima-
medial thickening and defective aortic distensibility without
endothelial dysfunction has been reported in recent stud-
ies [24]. Similar histological abnormalities have been found
in Marfan’s syndrome and bicuspid aortic valve, involving
cystic medial necrosis reported in 65% of dissected aortic
tissue [23]. The similar vascular damage suggests possible
involvement of the TGF- signalling pathway in the patho-
physiology of arterial disease in Turner’s syndrome, as in
Marfan’s syndrome or the Loeys Dietz syndrome [25,26].
The valve disease is predisposed to by extracardiac risk fac-
tors such as oestrogen deﬁciency, diabetes, dyslipidemia,
overweight and hypothyroidism if these are not controlled
[22,27].
Aortic dissection
Acquired and potentially severe cardiovascular complica-
tions explain the poorer median survival than in the general
population (70-years-old) with the excess cardiovascular
mortality responsible for almost half of deaths. The relative
risk of coronary artery disease was increased by a factor
of 2.1, that of cerebrovascular disease by 2.7 in one epi-
demiological study [27]. Aortic dissection usually preceded
by dilatation or aortic aneurysm is the most feared com-
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lication as it is fatal in the acute phase in 75% of cases.
t is responsible for 2 to 8% of deaths depending on the
eries [28—30] and was estimated to have an incidence of
6/100,000 Turner’s syndrome patients per year in a Dan-
sh series, occurring at an average age of 35-years-old,
ompared to 68-years-old in non-syndromic women [28].
ighty-seven cases have been published in the last 45 years
29]. Unlike the knowledge obtained in Marfan’s syndrome
he relationship between aortic dilatation and aortic dis-
ection is inadequately documented in Turner’s syndrome:
ortic dissections (3/166) have only been seen at values of
5mm/m2 and above, i.e. more than 37mm in the Matura
eries [15]. On the other hand Carlson describes two cases,
ne of which was 18-years-old, with aortic diameters less
han 28.5mm, i.e. below the 95th percentile. Risk factors
re found in 90% of cases: left heart disease +HBP (40%),
eft heart disease without HBP (35%) and HBP alone (15%)
29]. This justiﬁes aggressive anti-hypertensive manage-
ent in these patents as it is the most commonly associated
odiﬁable risk factor [21]. Around twenty cases of aortic
issection in non-hypertensive patients without congenital
eart disease (9.5—61-years-old) has been described, pro-
iding evidence for the role of speciﬁc vasculopathy. Finally,
ortic dissection is believed to complicate up to 2% of preg-
ancies in Turner’s syndrome implying careful selection of
otential candidates for medically assisted conception as
escribed further on [31].
ypertension
ypertension affects up to 25% of adolescents with Turner’s
yndrome and a higher percentage (40 to 60%) of adults:
21,27,32,33]. It is usually essential, although a renal or
ardiological abnormality, which is present in 20% of cases,
ust be excluded [21,34]. It mostly affects systolic pressure,
hich does not fall at night. Its mechanism has not been
learly identiﬁed: an increase in plasma renin activity has
een found in 50% of cases by some authors [34]. Abnormal
agosympathetic tone explaining relative tachycardia has
ecently been described [35]. Screening and follow-up are
erformed using blood pressure Holter (ABPM). Conﬁrmed
ypertension is an important risk factor for cardiovascu-
ar complications and justiﬁes antihypertensive treatment
ith the aim of restoring blood pressure values strictly to
ormal. Beta-blockers, which have been shown to be use-
ul in preventing cardiovascular complications in Marfan’s
yndrome, the CEI or ARA 2 should be preferred. Calcium
nhibitors may increase the risk of lymphodoema in these
atients.
lectrical abnormalities
lectrocardiographical abnormalities involving conduction
r repolarisation defects have been described and attributed
o neuro-autonomic dysfunction. Prolongation of the QT
nterval, usually moderate, has been reported from pae-ysrhythmias have yet been documented [36]. An electro-
ardiogram (ECG) must be included as part of the follow-up
nvestigations in these patients. The practical approach to
atients with long QT interval is the same as that recom-
ended in the general population.
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rowth hormone and the heart in Turner’s
yndrome
etrospective studies have not shown growth hormone treat-
ent to have any adverse cardiological effect either on
entricular or aortic dimensions, the risk of dissection or
n electrical abnormalities [37,38]. It may even have ben-
ﬁcial effects on the mechanical properties of the arterial
all, particularly distensibility [39].
ardiovascular follow-up
ethods [8,40]
cardiology assessment with a cardiologist skilled in con-
enital heart disease should be performed as soon as the
iagnosis is made. This involves a clinical examination with
xamination of the peripheral pulses, measurement of blood
ressures in all four limbs, an electrocardiogram ECG and
chocardiogram.
Echocardiography is used to investigate for congenital
eart diseases, particularly those affecting the left heart:
icuspid aortic valve, aortic obstruction and venous return
bnormalities. Ascending aorta measurements should be
erformed in a standardised and reproducible manner as
n Marfan’s syndrome, at four levels on a long axis left
arasternal end-diastolic view: aortic ring, sinus of Val-
alva, sinotubular junction and ascending aorta 10mm above
he sinus of Valsalva. Aortic diameters should be compared
gainst standard values deﬁnes as a function of body surface
rea by Roman in the absence of height-adjusted reference
alues for these patients [19].
MRI is recommended if the entire thoracic aorta cannot
e sufﬁciently visualised, particularly in adults or ado-
escents, before a possible pregnancy, and if the patient
as a past history of bicuspid aortic valve and/or surgi-
ally treated coarctation. In particular this can conﬁrm
he maximum dimensions of a dilated aorta and pro-
ide further information about the indication for surgery
39].
ollow-up intervals
f the patient has a past history of surgically treated coarcta-
ion of the aorta, bicuspid aortic valve and/or hypertension,
nnual follow-up is recommended with measurement of
lood pressure (possibly supplemented by ABPM), ECG and
chocardiography. An MRI can be performed every three to
ve years depending on the cardiologist’s opinion. If clin-
cally signiﬁcant advancing aortic dilatation is present, a
i-annual cardiology review is recommended.
In the absence of bicuspid aortic valve, past history of
oarctation or hypertension, clinical follow-up with annual
lood pressure measurement is recommended. A cardiology
ssessment with ECG, echocardiography and/or MRI can be
ffered every ﬁve years in the transition to adulthood and
efore any intended pregnancy.reventative management
isk factors
ontrol of cardiovascular risk factors due to the syn-
rome is recommended from childhood onwards: treatment
c
u
i
v
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f hypertension, diabetes, dyslipidaemia, management of
verweight and sedentary lifestyle [40—44], etc.
Patients with heart disease should be reminded regularly
f the need for endocarditis prophylaxis for any at risk pro-
edure.
ortic dilatations
n the absence of hypertension the utility of preventative
eta-blocker treatment as recommended for Marfan’s syn-
rome at least when moderate dilatation of the ascending
orta is present has not been demonstrated [45]. Similarly,
he use of sartans, which have been shown to have beneﬁt
n inhibiting the TGF signalling pathway in a mouse model
ith Marfan’s syndrome, needs to be conﬁrmed in patients
ith Turner’s syndrome [26]. The level of maximum dilata-
ion which justiﬁes preventative replacement surgery to the
scending aorta has not been established in this popula-
ion. It does however appear reasonable to consider the type
f medical/surgical management at values over 25mm/m2
ody surface area or an increase in aortic diameter more
han 10% per year [15]. Controlled prospective studies are
herefore needed to provide information about the indi-
ations for more aggressive management of these patients
17].
ardiology follow-up and pregnancy
pontaneous or medically assisted pregnancy carry a high
ardiological risk because of the increased risk of aortic
ilatation and therefore dissection. The United States sur-
ey of 146 patients with Turner’s syndrome treated by oocyte
onation showed no deaths in 101 pregnancies and a single
eath due to aortic dissection in one patient awaiting the
rocedure. In the same country over the same period, four
eaths were reported in Turner’s syndrome patients during
regnancy [31]. The risk of death in pregnancy appears to
e increased by more than 100 times. A past history of aor-
ic dissection, aortic dilatation or even bicuspid aortic valve
re relative contra-indications to any pregnancy [46].
A cardiology assessment with echocardiography or even
RI if the echocardiogram is insufﬁcient is therefore a
rerequisite to any planned pregnancy. Pregnant patients
hould be followed up in a level 3 maternity unit with mater-
al ultrasound in the ﬁrst and second trimesters and monthly
n the third trimester. A cardiology review should be per-
ormed in the 15 days after delivery.
onclusion
ongenital or acquired cardiological problems occur com-
only in Turner’s syndrome. They are potentially progressive
nd are responsible for severe complications, particularly a
isk of aortic dissection in young women. They justify aggres-
ive preventative management from childhood onwards,ongenital heart disease, and control of risk factors, partic-
larly HBP. Prospective studies are required to provide more
nformation about the utility of treatments liable to pre-
ent or delay aortic dilatation such as the beta-blockers or
artans in Turner’s syndrome.
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